Plain-English translation of NCT07608978 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing polatuzumab vedotin combined with five other medications to treat a specific type of aggressive lymphoma (diffuse large B-cell lymphoma) that has not been treated before. The study will measure how well this medication combination works and whether it is safe. If the cancer responds well to treatment, you would then continue taking two of the medications for up to one year to help prevent the cancer from coming back.
This type of lymphoma can be difficult to treat, and doctors want to see if this new medication combination can improve how many patients get better and stay cancer-free longer. This treatment targets specific features of the cancer cells that may make it work better than current standard treatments.
You likely qualify if…
You likely don't qualify if…
You would receive six cycles of treatment, with each cycle lasting 21 days. During each cycle, you would get intravenous (IV) infusions of the medication combination and take pills by mouth on specific days. Doctors would use CT or PET-CT scans to check how well the cancer is responding. If your cancer responds well, you would move to a maintenance phase where you continue taking two of the medications for up to one year, with regular check-ups to monitor your health and watch for any side effects.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China